Biomea Fusion, Inc. BMEA
0.62 USD -0.04 (-5.47%)
At closeNov 4, 2026, 4:00 AM EST
0.62 0.00 0.00%
Pre-market · Nov 4, 4:00 AM ET
0.6238 Day range 0.6877
0.552 52-week range 2.24
- YTD
- -49.69%
- 1 year
- -50.49%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers MaxCyte (NASDAQ:MXCT) shares rose 34.5% to $1.3 during Wednesday's regular session. The company's market cap stands at $102.6 million. Liquidia (NASDAQ:LQDA) stock moved upwards by 26.29% to…
benzinga.com Citizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price Target Citizens analyst Jonathan Wolleben reiterates Biomea Fusion (NASDAQ:BMEA) with a Market Outperform and maintains $7 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Liquidia (NASDAQ:LQDA) shares moved upwards by 41.0% to $37.8 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.4 billion. Greenland Mines…
benzinga.com State Street, Fastenal And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. futures were mixed. State Street fell 6.4% after missing sales estimates, while Biomea Fusion, Skydance and other stocks slid premarket.- benzinga.com HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $4 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $4 price target.
benzinga.com Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.
benzinga.com What’s Going On With Biomea Fusion (BMEA) Stock After Hours? Biomea Fusion reports Phase 1 BMF-650 results, with weight reduction and safety data from its oral GLP-1 drug trial.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 20.5% to $3.65 during Tuesday's after-market session. The market value of their outstanding shares is at $2.6 million. Circle8 Group…
benzinga.com Biomea Fusion BMF-650 Phase 1 Weight Loss Results Remain Preliminary, With Longer-Term Trials And Toxicology Studies Still Outstanding Safety and TolerabilityAcross the five active-dose MAD cohorts (n=40), all reported treatment-emergent adverse events (TEAEs) were mild or moderate. There were no severe or serious TEAEs,…
benzinga.com Biomea Fusion Reports Phase 1 Results For Oral GLP-1 Candidate BMF-650, Showing Consistent Weight Reduction And Encouraging Tolerability Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo.No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related…
benzinga.com Biomea Fusion Stock Climbs 7% After-Hours: What's Going On? Biomea Fusion shares rise after-hours before Phase I results for oral GLP-1 candidate BMF-650.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…
benzinga.com Biomea Fusion To Report Results From Phase I GLP-131 Clinical Study Evaluating BMF-650, Investigational Next-Gen Oral Small-Molecule GLP-1 Receptor Agonist, On October 13 Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company, today announced that it will report results from its Phase I GLP-131 clinical study…- benzinga.com Brookline Capital Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $10 Brookline Capital analyst Kumaraguru Raja initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Buy rating and announces Price Target of $10.